Swedish Orphan Biovitrum Performance and Valuation

The company has a market capitalization of around $14 billion, making it a significant player in the biotech industry.

Biovitrum's revenue has consistently grown over the years, with a compound annual growth rate (CAGR) of 15% from 2010 to 2019.

The company's profitability has also improved, with an operating margin of around 20% in 2019.

Swedish Orphan Biovitrum's strong financial performance is a testament to its successful business model and strategic decisions made by its leadership team.

Let's take a look at the financials of Swedish Orphan Biovitrum. The company has a significant amount of cash on hand, with a total of $1.06 billion in cash as of the most recent quarter.

Here are some key financial metrics to consider:

The company's debt-to-equity ratio is a notable 32.80%, indicating that it has taken on a moderate amount of debt to finance its operations.

The performance of SOBI.ST is a key metric to consider. As of 10/13/2025, the trailing total returns include dividends or other distributions.

The benchmark for SOBI.ST is the OMX Stockholm 30 Index (^OMX), which provides a standard for comparison.

Financial Statements are a crucial aspect of understanding a company's financial health. The Balance Sheet and Cash Flow section provides valuable insights into a company's liquidity and debt management.

Total Cash (mrq) is a significant indicator of a company's ability to meet its short-term obligations. With $1.06B in total cash, this company appears to have a solid foundation for its financial operations.

The Total Debt/Equity ratio (mrq) of 32.80% suggests that the company has a moderate level of debt compared to its equity. This ratio is a key indicator of a company's financial leverage.

Levered Free Cash Flow (ttm) of $2.66B indicates that the company is generating significant cash from its operations, which can be used to pay off debts, invest in new projects, or return value to shareholders.

Sobi reported net sales of SEK 7.7 billion in the third quarter, a 13% increase on a reported basis compared with last year.

On a similar theme: Enad Global 7

The company's strong growth is largely due to its successful products, which have been performing well in the market.

Sobi's Elocta was first to market in Europe among EHL treatments in hemophilia A, giving the company a head start in this area.

This success has allowed Sobi to raise its outlook for the year, with management now expecting revenue growth in the low double digits.

Sobi's adjusted EBITA margin is also expected to be in the mid- to high-30s as a percentage of revenue, a significant improvement from previous years.

The launch of once-weekly Altuviiio in Europe is expected to further extend Sobi's franchise despite competition from other companies.

Swedish Orphan Biovitrum AB (Sobi) has a significant market presence with a market capitalization of $108.15 billion.

The company's valuation measures also indicate a strong position, with a trailing P/E ratio of 24.87 and a forward P/E ratio of 17.21.

Sobi's valuation multiples are comparable to its peers, such as CSL and ALNY, with a price/earnings ratio of 20.38 and a price/book value of 3.03.

Here's a comparison of Sobi's valuation multiples with its peers:

Sobi's acquisition of CTI BioPharma is a strategic move to develop a rare haematology therapy, with a $1.7 billion investment.

Valuation is a crucial aspect of acquisition, as it helps determine the true value of a company.

Market capitalization, or market cap, is a key valuation metric that indicates the total value of a company's outstanding shares. For example, a company with a market cap of 108.15 billion dollars is considered a large-cap company.

The price-to-earnings (P/E) ratio is another important metric, which compares a company's stock price to its earnings per share. A P/E ratio of 24.87 indicates that investors are willing to pay 24.87 times the company's earnings for each share.

The PEG ratio, or price-to-earnings-to-growth ratio, is a more comprehensive metric that takes into account a company's growth rate. A PEG ratio of 1.58 suggests that the company's stock price is relatively high compared to its growth rate.

Here's a comparison of the P/E ratio for three companies: SOBI, CSL, and ALNY. The normalized P/E ratio for SOBI is 20.38, while CSL's is 20.31. ALNY's normalized P/E ratio is significantly higher at 650.87.

Additional reading: L E Lundbergföretagen

In terms of price-to-book value, SOBI's ratio is 3.03, while CSL's is 3.56. ALNY's price-to-book value is 242.99.

Price-to-sales (P/S) ratio is another metric that can indicate a company's value. SOBI's P/S ratio is 3.94, while CSL's is 4.44. ALNY's P/S ratio is 24.46.

A high P/S ratio may indicate that a company is overvalued, while a low ratio may suggest undervaluation.

You might like: CSL Limited

The $17B acquisition is a significant deal in the pharmaceutical industry. CTI BioPharma is being acquired by Swedish Orphan Biovitrum AB (Sobi). This acquisition aims to advance an oral kinase inhibitor treatment for a rare haematological disease. The companies intend to develop this therapy together.

Swedish Orphan Biovitrum AB conducts clinical trials to determine its go-to-market proposition and gain insight into its clinical operations, recruitment, and trial strategy.

The company has partnered with Biogen Idec to announce positive results from the A-LONG study.

Interim results from the B-YOND study support the long-term safety and efficacy of Alprolix in people with severe haemophilia B treated for up to two years.

Clinical trials are a crucial step in determining the effectiveness and safety of new treatments.

Companies like Swedish Orphan Biovitrum AB conduct clinical trials to gain insight into their operations, recruitment, and trial strategy.

Interim results from studies like the B-YOND study can support the long-term safety and efficacy of treatments like Alprolix for people with severe haemophilia B.

Positive results from studies like the A-LONG study announced by Biogen Idec and Swedish Orphan Biovitrum can be a significant milestone in the development of new treatments.

Clinical trials can involve treating patients for up to two years to assess the long-term effects of a treatment.

For your interest: Concord New Energy

Alprolix has shown a long-term clinical profile in people with severe haemophilia B, with interim results from the B-YOND study supporting its safety and efficacy after up to two years of treatment.

The B-YOND study found that Alprolix was effective in preventing bleeding episodes in people with severe haemophilia B.

Alprolix was approved by the European Commission in 2016 for the treatment of haemophilia B, and it maintained its orphan designation.

The European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for Alprolix in 2015, based on a Phase 3 study that showed potential for once- or twice-weekly prophylactic dosing regimens.

Here are some key facts about Alprolix's clinical profile:

The EMA's validation of Alprolix's MAA was a significant step towards its approval, and it marked an important milestone in the development of this treatment for people with haemophilia B.

Swedish Orphan Biovitrum has several competitors in the market, each with their own unique characteristics. Swedish Orphan Biovitrum is a public entity based in Sweden, specifically in Stockholm.

One of its competitors, BioGaia AB, is also a public entity based in Sweden, located in Stockholm. Another competitor, Probi AB, is a private entity based in Lund, Sweden.

In terms of size, Swedish Orphan Biovitrum has a significant number of employees, with 1,937 staff members. BioGaia AB has a much smaller workforce, with only 230 employees.

You might enjoy: When Will Orphan First Kill Be Released?

Here's a comparison of the key parameters of these companies:

Swedish Orphan Biovitrum is also larger than Probi AB, which has 157 employees. Hansa Biopharma AB, another competitor, has 140 employees. AMAG Pharmaceuticals Inc, a competitor based in the United States, has 440 employees.

Swedish Orphan Biovitrum AB has a commercialized product portfolio that's worth keeping an eye on.

Their marketed drugs are a significant part of their business, and it's interesting to note that understanding their product portfolio can help you stay ahead of the market.

With a diverse range of products, Swedish Orphan Biovitrum AB is a company to watch in the industry.

Broaden your view: Watch Orphan 2